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Abstract
Purpose Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient 
outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus 
and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable 
safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. 
Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and 
requires a multidisciplinary effort and a good knowledge of drug interactions.
Methods We reviewed the current evidence on the drug safety of targeted agents for metastatic breast cancer currently used 
in clinical practice in Italy, supported by the clinical experience of Italian oncologists with expertise in the field.
Results All oncologists had used CDK4/6 inhibitors in clinical practice and/or within a clinical trial. The clinical manage-
ment of toxicities, including dose adjustments, treatment interruptions, and concerns regarding special populations is dis-
cussed, and the management of relevant adverse events, related to individual agents and class-specific, toxicities is reviewed. 
Hematologic toxicities have the greatest impact on clinical management of the disease and on patients. Although toxicities 
associated with the new treatments result in more visits to the physician and more time and attention with patients, they are 
manageable, with no need for the oncologist to consult with specialist physicians.
Conclusions Based on the available evidence and current guidelines, we propose a series of practical recommendations for 
multidisciplinary clinical management of the various toxicities associated with the addition of targeted agents to endocrine 
therapy.
Keywords Abemaciclib · Advanced breast cancer · Everolimus · Neutropenia · Palbociclib · Ribociclib
Introduction
The development of targeted agents for the treatment of hor-
mone receptor (HR)-positive, HER2-negative locally advanced 
or metastatic breast cancer has significantly improved pro-
gression-free survival (PFS) and rates of objective response 
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and clinical benefit compared with conventional single-agent 
endocrine therapy [1–8]. Currently, approved targeted agents 
include everolimus, an oral inhibitor of the mammalian target 
of rapamycin (mTOR) [9] and three oral selective inhibitors 
of cyclin-dependent kinases (CDK) 4 and 6, palbociclib, ribo-
ciclib, and abemaciclib [10–12].
Compared with the well-characterized and easily manage-
able safety profile of endocrine therapies, usually related to 
symptoms typically associated with estrogen deprivation, 
including arthralgia, hot flashes, and fatigue, adverse events 
associated with targeted therapies are distinct and more com-
plex. Results from the registration trials have shown that com-
bining targeted agents with endocrine therapies substantially 
increases the incidence of grade 3–4 adverse events compared 
with conventional single-agent endocrine therapy [1, 2, 4, 5, 
7, 8]. Everolimus has been associated with stomatitis and non-
infectious pneumonitis, while neutropenia is the most com-
mon toxicity related to CDK4/6 inhibitors [13–18]. Prompt 
recognition and management of these toxicities is vital for 
treatment persistence and, therefore, for maximizing survival. 
However, this may pose a challenge to many oncologists, as 
experience in clinical practice with novel treatment strategies 
for metastatic breast cancer is still limited. In addition, for 
fear of adverse events, many oncologists may not prescribe 
targeted therapies to elderly or frail patients, precluding them 
from effective treatment options [14, 19]. Another issue of 
importance for optimal use of strategies combining endocrine 
therapy and targeted agents is knowledge of drug interactions 
related to everolimus and CDK4/6 inhibitors.
In the present paper, we review the relevant evidence con-
cerning drug interactions and safety profiles of everolimus and 
the CDK4/6 inhibitors in use in clinical practice in Italy for the 
treatment of HR-positive metastatic breast cancer and discuss 
the toxicities associated with this novel approach to the treat-
ment of breast cancer. Based on the available evidence and 
current guidelines, we propose a series of practical recom-
mendations for clinical management of the various toxicities 
associated with the addition of targeted agents to endocrine 
therapy.
Methods
A multidisciplinary panel of five Italian clinicians, includ-
ing an oncologist, a pharmacologist, a hematologist, a gas-
troenterologist, and a cardiologist, convened at a meeting 
organized within the NetworkER+ project (held in Rome, 
Italy in January 2018). A group of 20 oncologists from the 
HERMIONE network also attended the meeting. HERMI-
ONE is a network platform that was launched in February 
2017 to promote communication and collaboration among 
oncology centers and oncologists involved in the treatment 
of metastatic HR-positive breast cancer in Italy.
The main objectives of the NetworkER+ meeting were 
to: review current evidence concerning the drug interactions 
and safety profile of targeted agents used in metastatic breast 
cancer; produce recommendations for the optimal manage-
ment of drug interactions and toxicities related to targeted 
agents; focus on frail patients with metastatic breast cancer, 
namely the elderly and those with organ dysfunction.
Clinical experience
The 20 oncologists at the meeting were from Oncology Units 
treating ≥ 150 breast cancer cases per year, across the entire 
national territory. All had used CDK4/6 inhibitors in their 
clinical practice; 60% within a clinical trial. In their expe-
rience, hematologic toxicities have the greatest impact on 
both clinical management of the disease and on patients. 
The toxicities associated with the new treatments result in 
more visits to the physician and in more time and atten-
tion devoted to patients. However, they are considered to be 
manageable, with no need for the oncologist to consult with 
specialist physicians.
Drug interactions
Drug interactions are an important cause of morbidity. The 
most relevant pharmacokinetic interactions involve drugs 
that can inhibit or induce enzymes in the hepatic cytochrome 
P450 system [16]. Members of the CYP3A family of P450 
enzymes are probably the most important of all drug-metab-
olizing enzymes because of their abundance and ability to 
process a large number of chemically unrelated drugs from 
almost every drug class [16]. Strong CYP3A4 enzyme inhib-
itors in clinical use include the antibiotics clarithromycin, 
telithromycin, and erythromycin, and the antifungal agents 
ketoconazole and voriconazole; grapefruit juice is also a 
strong CYP3A4 inhibitor. Strong CYP3A4 inducers include 
the antibiotic rifampicin and antiepileptic agents such as bar-
biturates, phenytoin, and carbamazepine; herbal preparations 
(St. John’s wort) can also induce CYP3A4. Predicting drug 
interactions is not easy. A factor that further complicates the 
understanding of drug interactions is the finding that inhibi-
tors/inducers and substrates of CYP3A4 overlap with those 
of the drug-transporter protein P-glycoprotein (P-gp) [16]. 
P-gp acts as an efflux pump-exporting drugs, for example, 
into the intestinal lumen.
Everolimus and the CDK4/6 inhibitors palbociclib, 
ribociclib, and abemaciclib are administered orally and 
have different half-lives, undergo predominantly hepatic 
metabolism, and are substrates of CYP3A4; everolimus is 
also a substrate of P-gp (Table 1) [20–23]. The concomitant 
use of everolimus or a CDK4/6 inhibitor with inhibitors of 
CYP3A4 (or P-gp for everolimus) may, therefore, result in 
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an increased plasma concentrations and pharmacological 
effect of the targeted agent, while their concomitant use with 
an inducer of CYP3A4 (or P-gp for everolimus) may lead to 
lower plasma concentrations and decreased pharmacological 
effect. According to the labels of the four targeted agents, 
the concomitant use of strong CYP3A4 inhibitors or induc-
ers is not recommended (everolimus) or should be avoided 
(CDK4/6 inhibitors). If unavoidable, the dose of everolimus 
or CDK4/6 inhibitors should be adjusted as recommended 
(Table 2). Liver function tests should be performed before 
initiating treatment with abemaciclib and ribociclib and 
repeated every 2 weeks for the first two cycles, monthly for 
the next two cycles, then as clinically indicated [10, 12]. 
An additional relevant interaction exists for ribociclib with 
anti-arrhythmic drugs and other medications that prolong 
the QT interval on the electrocardiogram (ECG). Such medi-
cations should be avoided in patients receiving ribociclib. 
Ribociclib is also a strong to moderate inhibitor of CYP3A4 
and should be used with caution with CYP3A4 substrates 
that have a narrow therapeutic index. With the exception of 
palbociclib, the targeted agents can be taken regardless of 
food intake. Palbociclib should be taken with food, as its 
absorption and drug exposure were shown to be low in the 
fasted state [11, 24].
Overall, to minimize the risk of harm due to drug interac-
tions, it is important to be aware of possible interactions. It 
is imperative to ask patients about the use of other medica-
tions, including herbal products. At the same time, patients 
should be informed about drug interactions and instructed 
to not take any additional medication (including over-the-
counter and herbal products) during treatment with targeted 
therapies without first consulting with the oncologist. Rec-
ommended measures to reduce the risk of adverse effects 
include using an alternative treatment, adjustment of the 
dose of targeted agent, and close patient monitoring.
Safety data from clinical trials
Class-effect toxicities associated with the use of mTOR 
inhibitors include stomatitis, which encompasses inflamma-
tion and ulceration of the oral mucosal lining, non-infectious 
pneumonitis (a non-malignant inflammatory infiltration of 
the lung), infections, and metabolic adverse events (hyper-
glycemia and hyperlipidemia) [13].
According to a recent meta-analysis of six randomized 
controlled trials (RCTs) investigating CDK4/6 inhibitors 
in combination with an aromatase inhibitor or fulvestrant 
in women with advanced breast cancer, the most frequent 
adverse event (all grades) in the group treated with the com-
bination of CDK4/6 inhibitor plus endocrine therapy was 
neutropenia (65%) followed by diarrhea (49%), infections 
(44%), nausea (40%), fatigue (39%), and leukopenia (35%) 
[25]. Other safety issues reported in clinical trials include 
hepatobiliary toxicity (ribociclib, abemaciclib), prolongation 
of the QT interval on ECG (ribociclib), and venous throm-
boembolism (abemaciclib) [10, 12].
Stomatitis and pneumonitis
In the BOLERO-2 trial, everolimus-related toxicities 
included stomatitis, pneumonitis, and hyperglycemia [26]. 
These toxicities were generally of mild or moderate severity 
and, with the exception of pneumonitis, occurred early after 
everolimus initiation (within 8 weeks). Adverse events were 
generally manageable with dose reduction and interruption 
for a median duration of 7 days. Of note, appropriate dose 
reductions for toxicity did not have a negative impact on 
efficacy [27]. In a meta-analysis of five randomized, double-
blind phase three clinical trials of everolimus in patients with 
solid tumors, including breast cancer, renal cell carcinoma, 
carcinoid tumors, and pancreatic neuroendocrine tumors, the 
rate of stomatitis was 67% [16]. Stomatitis was mostly grade 
1–2, with grade 3–4 reported in < 10% of patients. Stomatitis 
did not adversely affect PFS. Of note, prophylactic use of a 
steroid mouthwash has been shown to substantially reduce 
the incidence and severity of stomatitis in patients undergo-
ing combination therapy with everolimus and an aromatase 
inhibitor [28].
Gastrointestinal toxicity
Cases of severe gastrointestinal (GI) bleeding during tar-
geted therapy with everolimus have been reported [29–31]. 
In two of these reports, gastric antral vascular ectasia 
(GAVE) was identified as the likely cause of bleeding [29, 
30]; GI bleeding was successfully treated with endoscopic 
hemostasis using argon plasma coagulation after treatment 
discontinuation. In another case, GI bleeding was associated 
with treatment initiation and resolved following discontinua-
tion [31]. Endoscopy revealed that the bleeding was second-
ary to erosive gastritis, and several endoscopic interventions 
were needed to achieve hemostasis.
The rapidly proliferating GI epithelium is one of the most 
vulnerable tissues to the effects of antiproliferative drugs. 
Indeed, GI events including nausea, vomiting, and diarrhea 
are shared by most anticancer drugs. A meta-analysis of four 
studies with CDK4/6 inhibitors (palbociclib, ribociclib) was 
performed to assess the risk of GI toxicities associated with 
CDK4/6 inhibitors [32]. Adding CDK4/6 inhibitors to endo-
crine therapy was found to marginally increase the incidence 
of any-grade decreased appetite, nausea, vomiting, and diar-
rhea with no significant increase in the risk of high-grade 
GI toxicities compared with control. In the MONARCH 2 
study, which demonstrated that abemaciclib significantly 
extends PFS when added to fulvestrant in women with 
advanced breast cancer whose disease had progressed while 
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on endocrine therapy, the most common adverse events in 
the abemaciclib–fulvestrant versus fulvestrant alone arms 
were diarrhea (86.4% vs. 24.7%), neutropenia (46.0% vs. 
4.0%), nausea (45.1% vs. 22.9%) and fatigue (39.9% vs. 
26.9%) [6]. In most cases, diarrhea was effectively managed 
using supportive treatment, such as antidiarrheal medica-
tions and/or dose adjustments. Diarrhea was also the most 
frequent adverse event in the MONARCH-3 trial investi-
gating abemaciclib plus a nonsteroidal aromatase inhibitor 
(NSAI) as initial therapy in postmenopausal women with 
advanced breast cancer [3]. Diarrhea was reported by 81.3% 
of patients, but was mostly of grade 1 (44.6%). The most fre-
quent grade 3 or 4 event was neutropenia (21.1% vs. 1.2% in 
the group with a NSAI alone), diarrhea (9.5% vs. 1.2%), and 
leukopenia (7.6% vs. 0.6%). Low-grade diarrhea was man-
aged in most cases with conventional antidiarrheal medica-
tions and dose adjustment.
Neutropenia
The frequencies of CDK4/6 inhibitor-related grade 3–4 
neutropenia reported in RCTs were highest with palbo-
ciclib (54–66%, PALOMA-2 and 3 trials) and ribociclib 
(27–59%, MONALEESA-2 trial) and lowest with abemaci-
clib (21–27%, MONARCH-2 and 3) [1–3, 6, 18, 33–35]. 
According to a detailed safety analysis of the PALOMA-3 
trial comparing fulvestrant plus palbociclib versus fulves-
trant alone (median follow-up, 8.9 months), neutropenia was 
the most common grade 3 (55%) and 4 (10%) adverse event 
in patients receiving combination therapy [18]. However, 
febrile neutropenia was reported only in 0.9% and 0.6% of 
patients treated with fulvestrant–palbociclib and fulves-
trant alone, respectively. Dose modifications for grade 3–4 
neutropenia did not compromise PFS. The consequences 
of myelosuppression experienced during palbociclib treat-
ment are different from those associated with chemother-
apy-induced myeloablation [18]. The neutropenia associated 
with CDK4/6 inhibitors is effectively and rapidly managed 
by dose delay, interruption, or reduction and without the 
use of granulocyte colony-stimulating factors (G-CSF). This 
suggests that mature white blood cells are present in the 
bone marrow and can rapidly enter the blood circulation 
when drug levels decrease [18]. In contrast, chemotherapy 
results in the destruction of progenitor cells leading to more 
persistent and severe neutropenia.
Elevation of liver enzymes
The CDK4/6 inhibitors, ribociclib and abemaciclib, have 
been associated with hepatobiliary toxicity [3, 4, 34, 35]. 
In the MONALEESA-2 study, grade 3 or 4 elevations in 
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in 9.3% and 5.7%, respectively, of patients receiving ribo-
ciclib plus letrozole versus letrozole alone and have also 
been observed with other CDK4/6 inhibitors in combination 
with aromatase inhibitors. Most cases of liver-enzyme eleva-
tion were asymptomatic and reversed by dose adjustment. A 
detailed analysis of the safety and health-related quality of 
life from the MONALEESA-2 trial confirmed that hepato-
biliary toxicity was more common in patients treated with 
ribociclib plus letrozole than in those treated with letrozole 
alone, with the onset of such events more common during 
the first 12 months of treatment (21.3% vs. 9.5% for riboci-
clib plus letrozole vs. letrozole alone) [34].
Abemaciclib was also associated with a higher rate of 
hepatic transaminase elevations in the abemaciclib arm of 
the MONARCH-3 trial [3]. These were generally manage-
able with dose reduction or dose omission and were resolved 
with drug discontinuation.
QTc prolongation
Some drugs can cause a delay in cardiac repolarization, 
measured as prolongation of the QT interval on ECG. Delay 
in cardiac repolarization can increase the risk of cardiac 
arrhythmias, most notably torsades de pointes [3]. In the 
MONALEESA-2 trial comparing ribociclib combined with 
letrozole versus letrozole alone for first-line treatment of 
postmenopausal women with advanced breast cancer, the 
most frequent adverse event in the ribociclib arm was neutro-
penia (74.3% vs. 5.2% in the letrozole alone arm), followed 
by nausea (51.5% vs. 28.5%), infections (50.3% vs. 42.4%), 
fatigue (36.5% vs. 30.0%), and diarrhea (35.0% vs. 22.1%) 
[33]. These events were mostly grade 1 or 2. An increase of 
more than 60 ms from baseline in the QTcF (QT corrected 
by Fridericia) interval occurred in nine patients (2.7%) in 
the ribociclib group and in no patients in the placebo group. 
In the second interim analysis of the MONALEESA-2 trial 
(at a median follow-up of 26.4 months), safety results were 
comparable with those reported in the first analysis [4]. 
A > 60 ms prolongation from baseline in the QT interval 
occurred in ten patients (3.0%) in the ribociclib plus letro-
zole group and one patient (0.3%) in the letrozole group. A 
total of 12 (3.6%) patients receiving ribociclib plus letrozole 
had at least one QT of > 480 ms versus two patients (0.6%) in 
the control arm; in the ribociclib plus letrozole group, 11 of 
these patients had been reported at the time of the first analy-
sis. Two of the 12 patients in the ribociclib plus letrozole 
group had received a concomitant prohibited medication 
with a known risk to prolong QT; three of the 12 patients 
had dose interruption, but this was due to QT prolongation 
only in 1 patient. No arrhythmia (torsades de pointes) was 
reported in the ribociclib group. Together these findings con-
firm that ECG changes observed with targeted therapies are 
mostly asymptomatic and that QT prolongations are man-
aged effectively by adjusting the ribociclib dose.
Clinical management of toxicities
Dose adjustments and/or temporary interruption due to 
adverse reactions are recommended for all targeted agents 
based on individual safety and tolerability [9–12]. Table 2 
shows the dose modifications recommended in the labels 
of everolimus, palbociclib, ribociclib, and abemaciclib. Of 
note, the labels state that if further dose reduction is required 
below the lowest dose indicated, treatment should be perma-
nently discontinued. Overall, dose adjustment is usually not 
required for adverse reactions of grade 1, while treatment 
should be discontinued when the adverse reactions are grade 
4. For grade 2 and 3 adverse reactions, temporary treatment 
interruption should be considered until symptoms improve 
to grade ≤ 1. When this improvement is achieved, treatment 
should be resumed at the next lower dose. For example, in 
patients developing grade 2 everolimus-related non-infec-
tious pneumonitis, everolimus should be interrupted until 
symptoms improve to grade ≤ 1; treatment should be rein-
itiated at 5 mg daily. If symptoms fail to improve within 
4 weeks, treatment should be permanently discontinued. The 
same is recommended for grade 3 non-infectious pneumoni-
tis; in this case, if toxicity recurs at grade 3 after resuming 
treatment at 5 mg daily, everolimus should be permanently 
discontinued. If patients develop grade 2 stomatitis, everoli-
mus should be interrupted until recovery to grade ≤ 1 and 
reinitiated at the same dose; if stomatitis recurs at grade 2, 
treatment should be interrupted until recovery to grade ≤ 1 
and reinitiated at 5 mg daily. In the case of grade 3 sto-
matitis, everolimus should be interrupted until recovery 
to grade ≤ 1 and resumed at 5 mg daily. The approach to 
Table 2  Dose modifications 
recommended for the 
management of adverse 
reactions associated with 
targeted therapies
Agent Starting dose First reduction Second reduction Third reduction
Everolimus 10 mg once daily 5 mg once daily Not applicable Not applicable
Palbociclib 125 mg once daily 100 mg once daily 75 mg once daily Not applicable
Ribociclib 600 mg once daily 400 mg once daily 200 mg once daily Not applicable
Abemaciclib
 Combination therapy 150 mg twice daily 100 mg twice daily 50 mg twice daily Not applicable
 Monotherapy 200 mg twice daily 150 mg twice daily 100 mg twice daily 50 mg twice daily
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management of other relevant safety issues related to tar-
geted therapies is discussed in detail below.
Management of neutropenia and prevention 
of infections
Neutropenia induced by CDK4/6 inhibitors is reversible and 
can be readily managed by dose interruption or modifica-
tion without compromising treatment efficacy. The propen-
sity to develop higher-grade neutropenia during treatment 
with CD4/6 inhibitors can generally be recognized within 
the first months of treatment [18]. Appropriately tailored 
dose adjustments should be promptly implemented to reduce 
the risk of recurrent episodes of severe neutropenia and/or 
febrile neutropenia [18]. It is, therefore, important to moni-
tor absolute neutrophil counts early during treatment so that 
timely dose adjustments can be implemented in patients 
experiencing grade 3–4 neutropenia.
Figure 1 shows the recommended algorithm for the man-
agement of neutropenia associated with palbociclib, riboci-
clib, and abemaciclib [10–12]. Options for management of 
neutropenia and infections include dose reduction or drug 
interruption. Patients who develop grade 2 neutropenia dur-
ing treatment have an increased risk of developing higher-
grade neutropenia and febrile neutropenia. They should, 
therefore, be closely monitored (complete blood count) 
throughout treatment with CDK4/6 inhibitors. As for infec-
tions secondary to neutropenia, antibacterial prophylaxis 
should be administered only if grade 4 neutropenia persists 
for > 7 days and particularly in the presence of mucositis. 
Vaccination against Streptococcus pneumoniae before ini-
tiating therapy and annual influenza vaccination is recom-
mended for all patients. The American Society of Clinical 
Oncology (ASCO) guidelines recommend hepatitis B virus 
(HBV) screening in all cancer patients treated with conven-
tional chemotherapy or targeted therapies [36]. Based on the 
serological profile of HBV infection, a different therapeutic 
strategy will be needed (i.e., treatment or prevention of viral 
reactivation) [37].
Management of diarrhea, nausea, and vomiting
In the absence of signs of infection, diarrhea should gen-
erally be managed using non-pharmacologic interventions, 
including hydration, appropriate diet, and avoidance of 
Fig. 1  Management of 
CDK4/6-related neutropenia as 
recommended in the labels of 
palbociclib, ribociclib, and abe-
maciclib. For the recommended 
dose adjustments, please refer 
to Table 2. ANC absolute 
neutrophil count, CBC complete 
blood count. *The label of 
abemaciclib does not differenti-
ate between grade 3 neutropenia 
with or without fever > 38.5 °C 
and/or infection. Reproduced 
with permission from Spring 
et al. [17]
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diarrhea-inducing agents. However, in the case of abe-
maciclib, the Summary of Product Characteristics directs 
that treatment with antidiarrheal agents, such as lopera-
mide, should be started at the first sign of loose stools [10]. 
Recurrent or high-grade diarrhea requires dose reduction. 
Antidiarrheal medication (loperamide) can also be used. 
Nausea and vomiting should be treated with antiemetics, 
including metoclopramide, prochlorperazine, haloperidol, 
or serotonin-receptor antagonists as needed. Caution should 
be taken when prescribing symptomatic therapies because 
of potential drug interactions (Table 1). Particular attention 
is needed with the concomitant administration of ribociclib 
with antiemetics (e.g., intravenous ondansetron, dolasetron, 
metoclopramide, diphenhydramine, haloperidol) because of 
the risk of QT interval prolongation [38, 39]. With regards to 
palbociclib, rabeprazole (a proton pump inhibitor) decreases 
its serum concentration and H2-receptor antagonists or 
locally acting antacids should be used for the management 
of nausea. Dexamethasone and aprepitant may, respectively, 
decrease or increase serum levels of palbociclib; possible 
alternatives are metoclopramide and domperidone [32].
QT interval prolongation
Prolongation of the QT interval has been frequently associ-
ated with cancer therapies, with or without targeted agents 
[40]. Substantial prolongation of QT (> 500 ms) is more 
frequent with targeted therapies [40]. Of note, the incidence 
of major arrhythmias and myocardial infarction caused by 
therapy-related QT prolongation is very low [40]. Patients 
at risk of QT prolongation or with QT prolongation before 
or during cancer therapy should be assessed as outlined 
in Fig. 2 [40]. In cancer patients, altered electrolyte levels 
(hypokalemia, hypocalcemia, and hypomagnesemia) are 
often due to reduced electrolyte intake, diarrhea, vomiting, 
fever with sweating, use of laxatives, and therapy with ster-
oids. Furthermore, the use of drugs with potentially syn-
ergic effects on QT prolongation (Table 1) and structural 
cardiomyopathy can also contribute to QT prolongation. A 
cardiologist should be consulted in the following cases: QT 
prolongation > 500 ms; prolonged QT during treatment and 
presence of symptoms of heart disease; history of arrhyth-
mias; history of presyncope or syncope with a likely car-
diac origin; prolonged QT and bradycardia < 60 bpm (these 
patients should undergo ECG monitoring in a cardiology 
unit).
When initiating treatment with ribociclib, the follow-
ing points should be kept in mind: (1) QT > 500 ms, severe 
arrhythmias, or sudden cardiac death related to targeted thera-
pies are very rare; (2) At the first manifestation of QT pro-
longation, a manual measurement should be performed; (3) 
If prolonged QT is confirmed, reversible electrolyte altera-
tions should be excluded; (4) Treatment with ribociclib can 
be initiated in patients with QT < 450 ms; (5) Avoid concomi-
tant administration of drugs that can prolong the QT; (6) ECG 
should be measured at baseline, 14 days from the beginning 
of treatment, and at the beginning of the second cycle of treat-
ment; (7) Electrolyte levels should be measured before ini-
tiating treatment and if there is an indication for additional 
monitoring.
Treatment of elderly and frail patients
A significant proportion of patients with breast cancer are 
aged ≥ 65 years. Management of toxicities related to targeted 
therapies may be particularly challenging in this age group 
because of the presence of comorbidities and frailty. Due to 
the frequent use of polytherapy by older patients, the manage-
ment of drug interactions may be particularly complex. Older 
patients are generally underrepresented in oncology clinical 
trials, including those that have investigated targeted thera-
pies for HR-positive, HER2-negative metastatic breast can-
cer [41]. Subgroup analyses and a recent systematic review 
have shown that adding everolimus or a CDK4/6 inhibitor to 
endocrine therapy is, however, a feasible strategy in patients 
aged ≥ 65 years, resulting in improved survival, response rates, 
and clinical benefit [19, 27, 41]. In these analyses, the safety 
profile of everolimus and CDK4/6 inhibitors was consistent 
with that observed for the overall study population [41]. As a 
consequence, according to the prescribing information, there 
is no need for dose adjustments of everolimus and CDK4/6 
inhibitors in patients aged ≥ 65 years, based exclusively on age 
[9–12]. Subgroup analyses have also shown that the toxicities 
induced by targeted therapies in older patients were effectively 
managed by dose interruptions or reductions, as in the overall 
population [19].
Based on published evidence, current guidelines, and per-
sonal experience, we strongly recommend initiating targeted 
therapy with CDK4/6 inhibitors in elderly patients at the full 
licensed dose. Close monitoring to ensure the early detection 
of adverse events is highly recommended, as toxicities may 
rapidly worsen in older individuals. Currently, no data are 
available regarding the use of CDK 4/6 inhibitors in patients 
with organ dysfunction; these patients should be managed as 
recommended in the labels of the various targeted agents.
Conclusions
The addition of targeted agents, everolimus, or CDK4/6 
inhibitors to endocrine therapy has considerably improved 
the outcomes of patients with metastatic HR-positive, 
HER2-negative breast cancer. This strategy is, however, 
associated with an increased risk of class-specific tox-
icities that are potentially serious. Most adverse events 
associated with targeted therapies have an early onset and 
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can generally be readily managed by dose adjustments 
and temporary interruptions (Box 1). Early treatment of 
adverse events is crucial. In clinical practice, the optimal 
implementation of targeted therapies will require a multi-
disciplinary effort, the ability to stratify patients according 
to the risk of adverse events, treatment individualization, 
and close patient monitoring. Efforts aimed at increasing 
patient awareness of treatment-related toxicities will also 
be required.
Box 1 Summary of main recommendations 
for management of toxicities associated 
with targeted therapies
• Where possible, strategies to prevent expected adverse 
events should be considered (e.g., prophylactic use of 
steroid mouthwashes to prevent stomatitis; vaccinations 
to prevent common infections).
• Early management of toxicities is very important, and 
thus the prompt recognition of signs and symptoms is 
crucial. Patients should be informed about treatment-
related toxicities.
• Dose reductions for grade 2–3 adverse events are fea-
sible in many instances, with no detrimental effect on 
efficacy. Grade 1 toxicities usually do not require dose 
modifications, while grade 4 toxicities should prompt 
permanent treatment discontinuation.
Fig. 2  Assessment of patients at risk of QTc prolongation or with QTc prolongation before or during cancer treatment. Reproduced with permis-
sion from Porta-Sanchez et al. [40]
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• Careful consideration of drug interactions (CYP3A4 
inhibitors/inducers, as well as QT-prolonging drugs) 
is required when prescribing medications for the treat-
ment of adverse events.
• The co-administration of strong inhibitors or inducers 
of CYP3A4 with everolimus and CDK4/6 inhibitors 
should be avoided. Alternative medications should 
be given (e.g., metoclopramide and domperidone as 
antiemetics; loperamide as antidiarrheal agent).
• Neutropenia induced by CDK4/6 inhibitors is revers-
ible and can be readily managed by dose interruption or 
modification without compromising treatment efficacy, 
as described in the drug labels.
• Antidiarrheal agents, such as loperamide, should be 
started at the first sign of loose stools with abemaci-
clib; otherwise, diarrhea induced by CDK4/6 inhibi-
tors should initially be treated with non-pharmacologic 
interventions; antiemetics can be used for nausea and 
vomiting, after evaluation of possible drug interactions.
• Liver function tests should be performed before initiat-
ing treatment with abemaciclib and ribociclib and liver 
function monitored throughout treatment.
• QT interval prolongation has been associated with tar-
geted therapies; however, major arrhythmias and myo-
cardial infarction have been rarely reported.
• Patients should be seen by a cardiologist when: QT pro-
longation is > 500 ms; prolonged QT during treatment 
and presence of symptoms of heart disease; history of 
arrhythmias; history of presyncope or syncope with 
a likely cardiac origin; prolonged QT and bradycar-
dia < 60 bpm.
• Older patients (≥ 65 years) can be treated with targeted 
therapies; the profile of adverse events is similar to that 
of younger patients. No dose adjustments are required 
based solely on age.
• Drug interactions need particular consideration in older 
patients on polytherapy.
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